Tevogen Bio

Historical price data

Tevogen Bio is a clinical-stage biotech focused on developing accessible, off-the-shelf T cell therapies for oncology, virology, and neurology. Its core achievement is the ExacTcell platform, which selects and expands naturally occurring, unmodified cytotoxic T lymphocytes (CTLs) for precise targeting of diseased cells. The company's strategy is to leverage this scalable, allogeneic technology to address large patient populations with commercially attractive and economically viable therapies. Its lead program, TVGN-489, is in Phase 1/2 trials for COVID-19 and Long COVID.

The ExacTcell platform selects and expands naturally occurring, genetically unmodified cytotoxic T lymphocytes (CTLs) that target disease-specific antigens presented by a single HLA molecule, enabling the development of off-the-shelf, precision T cell therapies.

Tevogen competes with autologous CAR-T leaders (e.g., Gilead, BMS), allogeneic cell therapy developers using gene editing (e.g., Allogene), and TCR therapy firms. Its differentiation lies in using unmodified, naturally occurring T cells, aiming for a better safety and cost profile.